Dr Cynthia McCormick Joins Lightlake Therapeutics
29 März 2011 - 4:37PM
Business Wire
Lightlake Therapeutics Inc (OTCBB:LLTP) has appointed Dr
McCormick as a senior clinical and regulatory advisor. She is the
former Director of the Division of Anesthetic, Critical Care, and
Addiction Drug Products at the Office of Drug Evaluation, Center
for Drug Evaluation and Research (CDER), Food and Drug
Administration (FDA). Here she oversaw the review and approval of
anaesthetic agents and drugs targeted for the treatment of pain and
addiction, which included naloxone.
Prior to this, Dr McCormick served as a medical reviewer in the
Division of Neuropharmacological Drug Products at the U.S. Food and
Drug Administration for five years. She is also the former Deputy
Director of the Division of Extramural Research at the National
Institute of Neurological Disorders and Stroke, at the National
Institute of Health (NIH).
Dr Roger Crystal, CEO of Lightlake remarked; ‘Dr McCormick will
join our distinguished panel of advisors. As she approved Naloxone
whilst at the FDA, her expertise here is invaluable to
Lightlake.’
About Lightlake Therapeutics
Lightlake Therapeutics is an early stage biopharmaceutical
company aiming to build a solid platform of pharmacological
treatments based on our expertise using opioid antagonists. Other
significant developments include the use of an opioid antagonist
nasal spray to address binge-eating obesity. A Phase II trial of
this product in Helsinki is due to be completed during 2011.
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes,” estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward-looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
www.lightlaketherapeutics.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024